Last $5.20 USD
Change Today 0.00 / 0.00%
Volume 845.3K
CRMD On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

cormedix inc (CRMD) Snapshot

Open
$5.22
Previous Close
$5.20
Day High
$5.58
Day Low
$5.03
52 Week High
02/26/15 - $5.58
52 Week Low
05/27/14 - $1.05
Market Cap
116.8M
Average Volume 10 Days
913.0K
EPS TTM
$-0.91
Shares Outstanding
22.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORMEDIX INC (CRMD)

Related News

No related news articles were found.

cormedix inc (CRMD) Related Businessweek News

No Related Businessweek News Found

cormedix inc (CRMD) Details

CorMedix Inc., a development-stage pharmaceutical and medical device company, intends to in-license, develop, and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases. The company’s product candidates include CRMD003 (Neutrolin) and CRMD004, an antimicrobial/antifungal and anticoagulant combination in liquid and gel formulations used for the prevention of catheter-related blood stream infections and maintenance of catheter patency in hemodialysis patients. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Bridgewater, New Jersey.

2 Employees
Last Reported Date: 03/31/14
Founded in 2006

cormedix inc (CRMD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $223.5K
Co-Founder, Vice Chairman, Chief Scientific O...
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2013.

cormedix inc (CRMD) Key Developments

CorMedix Inc. Receives Fast Track Designation for Neutrolin

CorMedix Inc. announced that the U.S. Food and Drug Administration (FDA) granted its request for Fast Track designation of its lead product candidate, Neutrolin® Catheter Lock Solution, pursuant to the Food and Drug Administration Safety and Innovation Act (FDASIA). CorMedix's Neutrolin is a novel formulation of taurolidine, citrate and heparin with1000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis, and biofilm to keep catheter's operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation. Fast Track designation is granted to drug products designed to treat a serious condition, for which clinical data has been generated and shown to potentially address an unmet medical need. The Fast Track designation of Neutrolin provides CorMedix with the opportunity to meet with the FDA on a more frequent basis during the review process, and also ensures an expedited review of any marketing application. Neutrolin has shown antimicrobial activity against many of the pathogens that are known to pose a serious threat to public health by causing blood-stream infections in ICU, oncology and hemodialysis patients. CorMedix intends to expand on the previously collected clinical data by conducting clinical trials with Neutrolin® Catheter Lock Solution in oncology, hemodialysis and intensive care unit patients, where catheter-related blood stream infections and clotting can be life-threatening. The request for Fast Track designation was followed by a December 2014 submission to the FDA requesting Neutrolin be designated a Qualified Infectious Disease Product (QIDP). Designation of Neutrolin as a QIDP could secure incentives, such as the 5 year extension of marketing exclusivity, for pursuing marketing approval in the U.S.

CorMedix Inc. Finalizes First Middle East Neutrolin Sales/Distribution Agreement in the Kingdom of Saudi Arabia

CorMedix, Inc. announced the first signed Middle East sales/distribution agreement for lead product Neutrolin with distributor Arabian Trade House in the Kingdom of Saudi Arabia. CorMedix's Neutrolin is a novel formulation of taurolidine, citrate and heparin with 1,000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis, and biofilm to keep catheter's operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation.

CorMedix, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 10:00 AM

CorMedix, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 10:00 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRMD:US $5.20 USD 0.00

CRMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRMD.
View Industry Companies
 

Industry Analysis

CRMD

Industry Average

Valuation CRMD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORMEDIX INC, please visit www.cormedix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.